Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine
| Autor: | E.M. Rouppe van der Voort, Carla C. A. M. Peeters, J T Poolman, A.J. Kuipers, L.C. Sundermann, P van der Ley, Margje Schuller, H.C. Rümke, J. Meulenbelt |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Blood Bactericidal Activity Blotting Western Porins Enzyme-Linked Immunosorbent Assay Meningococcal vaccine medicine.disease_cause Microbiology medicine Humans General Veterinary General Immunology and Microbiology biology Neisseria meningitidis Immunogenicity Public Health Environmental and Occupational Health biology.organism_classification Antibodies Bacterial Virology Meningococcal Infections Infectious Diseases Bacterial Vaccines Humoral immunity biology.protein Molecular Medicine Electrophoresis Polyacrylamide Gel Neisseriaceae Antibody Bacterial outer membrane |
| Zdroj: | Vaccine. 14:1009-1015 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/0264-410x(96)00001-1 |
| Popis: | A meningococcal outer membrane vesicle (OMV) vaccine was prepared from two production strains designed to express three serosubtype-specific class 1 outer membrane proteins or PorA. The resulting hexavalent PorA OMV vaccine contained the serosubtypes P1.7,16; P1.5,2; P1.19,15; P1.7h,4; P1.5c,10; P1.12,13 and were used to immunize adult volunteers. A single immunization with two dosages, 7.5 and 15 micrograms of the individual PorAs, was studied. The vaccine was considered safe for further use. Approximately half of the volunteers demonstrated a fourfold increase in bactericidal antibody activity against six test strains expressing the specific PorAs when given the higher dosage. This bactericidal activity was found to be directed against PorA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect